Table 11 The PK parameters for Equation11modeling doxorubicin for Moreira et al. [[28]] with paclitaxel present

1,2

$8.86\left|\frac{1-0.0231X_{\mathit{\text{DOX}},2}^{3.12}}{1+0.157X_{\mathit{\text{DOX}},2}^{0.89}}\right|\left|1+\frac{0.0010X_{\mathit{\text{PTX}},1}}{1+0.00002X_{\mathit{\text{PTX}},1}}-\frac{0.0003X_{\mathit{\text{PTX}},2}}{1+0.106X_{\mathit{\text{PTX}},2}}\right|$

1,3

$3.69\left|\frac{1+3.09X_{\mathit{\text{DOX}},3}^{1.02}}{1+1.61X_{\mathit{\text{DOX}},3}^{0.95}}\right|$

1,4

$0.375\left|1+0.0003X_{\mathit{\text{DOX}},1}^{2.99}\right|\left|\frac{1+0.375X_{\mathit{\text{DOX}},4}^{1.59}}{1+0.0222X_{\mathit{\text{DOX}},4}^{0.31}}\right|$

2,0

$0.264\left|1+0.00002X_{\mathit{\text{DOX}},2}^{1.90}\right|\left|1-\frac{0.498X_{\mathit{\text{PTX}},2}}{1+0.101X_{\mathit{\text{PTX}},2}}\right|$

2,1

$0.102\left|\left(1+0.00001X_{\mathit{\text{DOX}},2}^{1.71}\right)\frac{1+11.2X_{\mathit{\text{DOX}},1}^{0.90}}{1+0.181X_{\mathit{\text{DOX}},1}^{0.91}}\right|\left|1-\frac{0.0010X_{\mathit{\text{PTX}},1}}{1+0.00002X_{\mathit{\text{PTX}},1}}+\frac{0.240X_{\mathit{\text{PTX}},2}}{1+0.350X_{\mathit{\text{PTX}},2}}\right|$

3,1

$0.0369\left|\frac{1+1.74X_{\mathit{\text{DOX}},1}^{0.96}}{1+0.298X_{\mathit{\text{DOX}},1}^{1.48}}\right|$

4,1

$0.0052\left|\left(1-0.00001X_{\mathit{\text{DOX}},4}^{1.14}\right)\frac{1+6.42X_{\mathit{\text{DOX}},1}^{1.02}}{1+0.154X_{\mathit{\text{DOX}},1}^{2.17}}\right|$